CISPLATIN, DOXORUBICIN, AND CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CARCINOMA

  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (5) , 465-467
Abstract
Nine of 19 patients (47%) with widespread or recurrent endometrial carcinoma responed to chemotherapy with cisplatin, doxorubicin, and cyclophosphamide. Two complete clinical responses and 7 partial responses were acheived. A "2nd-look" laparotomy documented the complete response in 1 patient. The addition of cisplatin to doxorubicin and cyclophosphamide increased toxicity without increasing the antitumor activity previously reported for the 2-drug combination. Performance status had a marked influence on response, while sites of metastases, amount of residual disease and histologic grade did not affect the response rate. A schema for the treatment of patients with endometrial carcinoma with progestins and/or cytotoxic chemotherapy is suggested.